Older adults sent home from the hospital with a new sedative prescription faced a measurably higher risk of falls, repeat hospital visits, and death, according to a large Canadian study that tracked more than 1.86 million patients. Researchers reported that the risk of a fall was about 20% higher in people who received a new prescription for a sedative such as a benzodiazepine at discharge, with new benzodiazepine prescriptions in particular linked consistently to worse outcomes.
Why the finding matters for older patients
Sedatives are commonly prescribed around hospital stays to manage sleep problems, anxiety, or agitation, and the transition home is a moment when medication lists often expand. This study zeroes in on that handoff and finds that starting a sedative at that point is associated with real harm in the following weeks, which is a pointed concern for a population already vulnerable to falls.
Falls are not a minor issue in older adults. They are a leading cause of injury, loss of independence, and death in that age group, so a 20% relative increase in fall risk tied to a specific prescribing decision is the kind of signal clinicians pay attention to. The study’s framing, that a new sedative at discharge carries downstream risk, points to a decision point that is potentially modifiable rather than an unavoidable feature of aging.
The distinction the researchers draw is important. According to the reporting, individuals with prior exposure to these medications did not experience the same increased hazards, which suggests the danger is concentrated in new starts rather than in ongoing use. That nuance shapes how the finding might be applied: the concern is about initiating a sedative in someone who was not already taking one, especially at the fragile moment of hospital discharge.
What the study measured
The analysis examined more than 1.86 million adults aged 66 and older who were discharged from hospital, covering a long span from April 2003 through August 2023. That scale and time range give the results statistical weight and reduce the chance that the association is a quirk of a small or unusual sample. The work was published in the Canadian Medical Association Journal, according to the coverage reviewed here.
Beyond the 20% higher fall risk, the researchers report that the risk of an emergency department visit, hospital readmission, and death within 30 days was also increased among those who received a new sedative prescription. In other words, the association was not limited to falls alone but extended to a cluster of serious outcomes in the month after leaving the hospital, as summarized in reporting on the study.
The drug-specific pattern adds detail. New benzodiazepine prescriptions were consistently associated with increased risks of falls, emergency visits, readmissions, and death. By contrast, the study found that certain sedating antidepressants, trazodone and mirtazapine, were not associated with an increased fall risk, which indicates the effect was not uniform across every medication that can cause drowsiness.
How to read the results and what remains open
An essential caveat is that this is an observational study, and observational designs establish association rather than proof of cause. The researchers describe an increased hazard tied to new sedative prescriptions, but factors that lead a clinician to prescribe a sedative at discharge could themselves contribute to the outcomes measured. The finding is a strong, large-scale signal, not a demonstration that the drugs alone cause the falls.
Even with that limitation, the practical implication is reasonably clear and cautious: starting a benzodiazepine or similar sedative in an older adult at hospital discharge is associated with a worse 30-day course, and that is a conversation worth having between patients, families, and prescribers. The data point specifically to new starts, so someone already stable on a long-term medication is in a different situation than someone being handed a first prescription on the way out the door.
Some specifics are not detailed in the available reporting, including the absolute, as opposed to relative, increase in fall risk and the precise definitions the researchers used for each outcome. Those details live in the full journal article. For readers, the actionable takeaway is not to stop any medication on their own, but to ask whether a newly prescribed sedative is necessary at discharge, and whether safer alternatives exist, given that the study found no elevated fall risk for trazodone and mirtazapine. Anyone with questions about a specific prescription should raise them with the prescribing clinician rather than acting on a headline.
More from Morning Overview
- The NSA issues an urgent warning to all phone users about a setting most people leave on
- 5,000-year-old wolves on remote island upend domestication theory
- Scientists may have found a Type II civilization
- EPA finally kills ‘stupid feature’ in 60% of U.S. cars after 14 years of driver rage
*This article was researched with the help of AI, with human editors creating the final content.
